Homo diabesus: involvement of metabotrophic factors by Aloe, Luigi et al.
Received 15 November 2013, accepted 7 December, 2013
Correspondence: Dr George N. Chaldakov, Laboratory of Cell Biology, Department of Anatomy and Histology, Medical University, 
BG-9002 Varna, Bulgaria. Tel.: 359 052 754 394, E-mail: chaldakov@yahoo.com
Abstract 
Diabesity is a new term which refers to type 2 diabetes mellitus and obesity found in one 
individual, hence Homo diabesus. Previously we presented our hypothesis of metabo-
trophic factors (MTF), also termed metabotrophins. Onward we described Homo obesus 
(man obese) as a metabotrophin-deficient species. Now - as a phenotypic variety of this 
species - we introduce H. diabesus. Endogenous MTF are in general signaling proteins 
able to improve cardiovascular and metabolic homeostasis including that of lipids, glu-
cose, energy, inflammation, angiogenesis, and cognition. Hence pharmacological ma-
nipulations of the secretion and/or signaling of MTF might bring a therapeutic benefit 
for H.  diabesus. Here we Dance Round the hypothesis that deficit and/or dysfunction 
of MTF may lead to diabesity. Arguably, an updated list of MTF including nerve growth 
factor, brain-derived neurotrophic factor, adiponectin, humanin, irisin and other  adi-
pose- and nonadipose-derived bioactive molecules is presented. Overall this may culti-
vate a novel pathogenic and therapeutic thinking for cardiometabolic disease.  
Adipobiology 2012; 5: 45-49
Key words: type 2 diabetes, obesity, adipokines, NGF, BDNF, metabotrophins, 
cardiometabolic disease
HOMO DIABESUS:  
inVolVeMent of MetAbotroPhiC fACtors
Luigi Aloe1, Anton B. Tonchev2, Marco Fiore1, and George N. Chaldakov2
1Institute of Cellular Biology and Neurobiology, National Research Council (CNR), Rome, Italy and 2Laboratory of Cell 
Biology, Department of Anatomy and Histology, Medical University, Varna, Bulgaria
introduction
Today, the most widespread disease 
around the world is not AIDS or ma-
laria or any other transmissible disease 
- it is obesity, the major global disease, 
globesity. Although the pathogenesis is 
not yet completely understood, there 
is now solid evidence that type 2 dia-
betes mellitus is a disease of the obese 
man (Homo obesus) (1). New clini-
cal trials demonstrate that as little as 
5% body weight loss is sufficient to 
prevent most obese subjects with im-
paired glucose tolerance developing 
type 2 diabetes. Since type 2 diabetes 
is obesity dependent, the term diabesi-
ty was adopted (2,3), and herein Homo 
diabesus is introduced.
Adipose tissue: the renaissance 
of a seemingly ubiquitous tissue 
One of biggest recent achievements in 
studying cardiovascular and metabol-
ic diseases (atherosclerosis, hyperten-
sion, obesity, type 2 diabetes, metabol-
ic syndrome, and Alzheimer’s disease) 
is associated with the ”rediscovery” of 
a neglected tissue, the adipose tissue.
Adipose tissue considered as pas-
sive storage-release of lipids by most 
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cell biologists and pathologists for a long period of time, can no 
longer be ignored in almost any biomedical field. The last 19-
20 years, that is, the time after Jeffrey Friedman’s discovery of 
leptin, have seen it rise above the horizon to take center stage 
in so many syndromes and diseases that it leaves most scientists 
and medical doctors astonished. There are two major subtypes 
of adipose tissue, white adipose tissue (WAT) and brown adi-
pose tissue (BAT), to which were recently added brite (brown in 
white) adipose tissue; also brown adipocytes found in skeletal 
muscles are referred to as bruscle (brown in muscle) adipocytes 
(4). Cumulatively, such an adipocentric approach has revealed 
that while BAT is major thermogenic organ, WAT is the body’s 
largest endocrine and paracrine organ producing multiple sign-
aling proteins collectively termed adipokines (5-11), with nerve 
growth factor (NGF) and brain-derived neurotrophic factor 
(BDNF) being also produced from adipose tissue (12). 
Multiple life of neurotrophins
The past three decades has witnessed a number of breakthroughs 
in the study on Rita Levi-Montalcini’s NGF, including the family 
of proteins termed neurotrophins (NGF, BDNF, NT3/4 alike). 
Studies have revealed that the neurotrophins NGF and BDNF 
are not only stimulating for  nerve growth and survival, but also 
exert trophic effects over (i) immune cells, acting as immunotro-
phins, (ii) keratinocytes, enterocytes, prostate and breast epithe-
lial cells,  acting as epitheliotrophins, and (iii) endothelial cells, 
acting as angiogenic factors (reviewed in 13).  
In 2003 we, for the first time, enriched the NGF-ome with 
one more expression, that is, metabotrophic action on glucose, 
lipid, energy, pancreatic beta cell and cardiovascular homeosta-
sis, and thus, together with BDNF, designated metabotrophins 
(from Greek metabole, and trophe, nutrition, means “nutritious 
for metabolism”) (14-16). Onward, the proof-of-hypothesis was 
based on results demonstrating that the circulating and/or tis-
sue levels of NGF and BDNF are (commonly) decreased in ath-
erosclerosis and metabolic syndrome (17,18), type 2 diabetes 
(19,20), depression and other psychiatric diseases (see 13), and 
in Alzheimer’s disease which nowadays is considered as type 3 
diabetes (21-23, also see Viviana Triaca’s review in this volume 
of Adipobiology).
implication of nGf and bdnf in cardiometabolic disease: 
results of a dream 
During his student life at the Medical University, Varna, Bul-
garia, one of us (GNC) used to work four years (1962-1966) as 
Research Associate at the Department of Pharmacology. It was 
that period of time when he for the first time “met” Professor 
Rita Levi-Montalcini, reading her papers on NGF. Since then he 
has being infected by this talented molecule, and thought how 
to reach her Institute in Rome, Italy. Although some colleagues 
told him that it is a very difficult pursuit, he continued to believe 
more in the art of dream as presented by Emily Dickinson’s To 
Make a Prairie (To make a prairie it takes a clover and one bee,/ 
One clover, and a bee,/…The dream alone will do,/ If bees are few.)
On its road, in 1997 he has applied for NATO-CNR Research 
Fellowship, which required acceptance letter by the host in-
stitution, RLM’s Institute of Neurobiology, National Research 
Council (CNR), Rome. Dr Luigi Aloe, Research Director of the 
Institute, provided such a letter, consequently awarded him the 
Fellowship. Thus in June 1998 GNC appeared in the Institute of 
Neurobiology in Rome. During this first four months there as 
well as almost each year further on he was pleased of common 
research work, producing a “paradigm shift” from neurotro-
phins to metabotrophins in cardiometaboic disease.
In our further research pursuit of MTF, we have, for the first 
time, published data of reduced circulating levels of NGF and 
BDNF in patients in advanced stage of metabolic syndrome as 
compared with healthy subjects (17,18). Contrary, the circulat-
ing levels of NGF and BDNF were significantly elevated in pa-
tients in early stage of metabolic syndrome (24). Whether the 
metabotrophic reserve of the organism is discharged with the 
progression of metabolic syndrome, remains to be elucidated.
In an attempt to “close” the metabotrophic “loop” in cardio-
metabolic disease, we have measured circulating levels of NGF 
and BDNF in patients with acute coronary syndromes, and 
found they are significantly reduced (25, also see 26). Another 
own study revealed altered levels of NGF in pancreas and brain 
in streptozotocin-induced diabetes (27). Recently, we found that 
in response to experimental stress or diabetes, the amount of 
NGF and BDNF was altered both in WAT and BAT (12).
Selected proof-of-metabotrophic concept examples derived 
from other laboratories are: (i) pancreatic beta cells secrete 
NGF and express its receptor tyrosine-kinase A (TrkA), find-
ings being implicated in the pathogenesis of diabetes melli-
tus (28, also see the research article  of Marcia Hiriart et al 
in this volume of Adipobiology), and (ii) mutations affecting 
Bdnf gene (encoding BDNF) in mice or Ntr2k2 gene (encoding 
the high-affinity BDNF receptor TrkB) in patients are associ-
ated with hyperphagia and severe obesity (1,13 and references 
therein).  Metabotrophic effects of NGF and BDNF are sum-
marized in Table 1. 
Conclusion and perspective 
We have presented an extended version of our hypothesis of 
the significance of adipose and nonadipose-derived MTF in the 
pathogenesis of cardiovascular and metabolic diseases. In this 
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context, the recent discovery of  (i) humanin, a mitochondria-
derived peptide expressing neuro- and metabotrophic effect 
(29,30), and (ii) irisin, a myokine/adipokine  involved in the 
browning of WAT (31,32), may open a further perspective for 
the therapy of Homo diabesus. Selected list of endogenous MTF 
is presented in Table 2.  It may open new windows for the search 
of exogenous MTF, such as (i) small molecules boosting secre-
tory and/or signaling pathways of MTF (reviewed in 1,13), and 
(ii) incretin mimetics and receptor agonists, because the insu-
linotropic hormone glucagon-like peptide-1 (GLP-1) and  ex-
endin-4, a GLP-1 receptor agonist, exert neuro- and metabo-
trophic effect (33,34). 
The future challenge is therefore to cul tivate a neuro-me-
tabotrophic thinking about how we can make MTF secretion 
and signaling work for the benefit of human’s health. This may 
also help Homo diabesus to enjoy both physical and mental 
quality of life. 
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Table 1. Metabotrophic effects of NGF and BDNF* 
NGF shares homology with proinsulin
NGF/BDNF are produced by pancreatic beta cells and exert insulinotropic effect
NGF/BDNF are trophic factors for pancreatic beta cells, also improve beta cell transplantation
NGF up-regulates expression of LDL receptor-related protein
NGF up-regulates expression of PPARgamma
NGF inhibits glucose-induced down-regulation of caveolin-1
NGF improves skin and corneal wound healing
NGF may improve vascular (atheroma) wound healing
NGF rescues silent myocardial ischemia in diabetes mellitus
NGF improves diabetic erectile dysfunction
NGF and BDNF suppress food intake  
Healthy lifestyle increases brain and/or circulating levels of NGF/BDNF
An atherogenic diet decreases brain BDNF levels
BDNF-deficient mice develop abnormalities similar to the metabolic syndrome 
BDNF improves cognitive processes
* Modified from (13). For references see the text, also (39-42).
Table 2. selected list of endogenous metabotrophic factors*
Secretory proteins
NGF, BDNF, Ciliary neurtrophic factor, Neuron-derived neurotrophic factor
Adiponectin, Irisin, Humanin, Omentin, Chemerin, Apelin, Otopetrin 1 
Interleukin-10, Metalothionein-I,-II, Glucagon-like peptide-1
Intracellular proteins
sitruins, PPAR-gamma, Uncoupling protein-1 (UCP-1) 
* Modified from (1). For references see the text, also (35-43).
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